首页> 中文期刊> 《上海医药》 >治疗COPD的新型支气管扩张剂的研发进展及市场情况

治疗COPD的新型支气管扩张剂的研发进展及市场情况

         

摘要

Chronic obstructive pulmonary disease (COPD) is a common disease of respiratory system. Bronchodilators are the main drugs to control the symptoms of COPD, and can be divided intoβ2-agonists, anticholinergic agents and theophylline drugs. Long-acting β2-agonists in combination with either anticholinergic agents or glucocorticoid can obviously control the symptoms of COPD, which possess such characteristics as the remarkable enhancement of bronchodilatory effect, long duration of action, reduction of adverse reaction in clinical application and have become one of the hotpoints in research and development of drugs for the treatment of COPD. The mechanism, foreign development status, sales and domestic research progress of bronchodilators are reviewed.%COPD是常见的呼吸系统疾病。支气管舒张剂是控制COPD症状的主要药物,支气管扩张剂又分为β2-受体激动剂、抗胆碱药和茶碱类药物。临床研究表明,长效β2-激动剂+抗胆碱药、长效β2-激动剂+糖皮质激素合用有明显的控制COPD症状的作用,具有支气管舒张作用明显增强、作用持续时间长、不良反应减少等特点。近年来已经成为COPD治疗药物研究开发的热点之一。本文就其作用机制、国外上市开发现状、国外销售情况及国内研究开发进展等进行综述。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号